Comparative Pharmacology
Head-to-head clinical analysis: VIRA A versus VIRAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIRA A versus VIRAZOLE.
VIRA-A vs VIRAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vidarabine (VIRA-A) is a purine nucleoside analog that inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination. It also inhibits ribonucleotide reductase, reducing viral DNA synthesis.
Ribavirin, the active ingredient in Virazole, is a synthetic nucleoside analog that inhibits viral RNA synthesis by competing with endogenous nucleotides for incorporation into viral RNA, leading to chain termination and inhibition of viral replication. It also has immunomodulatory effects.
15 mg/kg/day IV infused over 12-24 hours for 7 days.
Inhalation: 20 mg/mL solution via small particle aerosol generator (SPAG-2) for 12-18 hours per day for 3-7 days. Oral: Not FDA-approved for oral use; investigational oral dose 600-2400 mg/day in divided doses.
None Documented
None Documented
Vidarabine: 0.17-0.25 hours (rapidly deaminated to arabinosylhypoxanthine). Arabinosylhypoxanthine: 3.5-5.5 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment.
Terminal elimination half-life: oral administration ~24-36 hours; intravenous ~24 hours; inhalation systemic half-life ~24 hours. Clinical context: Prolonged half-life allows once-daily or twice-daily dosing, but accumulation may occur in renal impairment.
Primarily renal: approximately 40-70% of dose excreted unchanged in urine via glomerular filtration and tubular secretion. A smaller fraction (10-20%) is eliminated as the metabolite hypoxanthine arabinoside. Fecal excretion accounts for <5% of the dose.
Renal excretion as unchanged drug and metabolites; approximately 40% of an oral dose is excreted unchanged in urine, with 30-40% as metabolites; fecal elimination is minor (<10%).
Category C
Category C
Antiviral (Nucleoside Analog)
Antiviral (Nucleoside Analog)